Hydrolytically releasable prodrugs for sustained release nanoparticle formulations
US9233163B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2011 |
| Grant date | Jan 12, 2016 |
| Priority date | — |
| Expiry date | Apr 8, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08B37/0021
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.